| 摘要 |
<p>HIV replication inhibitors of formula R1 is hydrogen; aryl; formyl; C1-6alkylcarbonyl; C1-6alkyl; C1-6alkyloxycarbonyl; R2, R3, R6 and R7 are hydrogen; hydroxy; halo; C3-7cycloalkyl; C1-6alkyloxy; carboxyl; C1-6alkyloxycarbonyl; cyano; nitro; amino; mono- or di(C1-6alkyl)amino; polyhaloC1-6alkyl; polyhaloC1-6alkyloxy; -C(-O)R9; optionally substituted C1-6alkyl, C2-6alkenyl or C2-6alkynyl; R4 and R5 are hydroxy; halo; C3-7cycloalkyl; C1-6alkyloxy; carboxyl; C1-6alkyloxycarbonyl; formyl; cyano; nitro; amino; mono- or di(C1-6alkyl)amino; polyhaloC1-6alkyl; polyhaloC1-6alkyloxy; -C(-O)R9; cyano; -S(-O)rR9; -NH-S(-O)2R9; -NHC(-O)H; -C(-O)NHNH2; -NHC(-O)R9; Het; -Y-Het; optionally substituted C1-6alkyl, C2-6alkenyl or C2-6alkynyl; R5 is pyridyl, -C(-O)NR5aR5b; -CH(OR5c)R5d; -CH2-NR5eR5f; -CH-NOR5a; -CH2-O-C2-6alkenyl; -CH2-O-P(-O)(OR5g)2; -CH2-O-C(-O)-NH2; -C(-O)-R5d; X is -NR1-, -O-, -CH2-, -S-; pharmaceutical compositions containing these compounds as active ingredient and processes for preparing said compounds and compositions.</p> |
